Niche CDMO adds spray drying for highly potent drugs28 Mar 2018
The investment makes Idifarma one of only three companies in the world offering this type of contract development and manufacturing spray drying service.
IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few CDMO to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.
The Spanish CDMO, which specialises in niche and highly potent products, will be one of only three companies in the world offering this type of contract development and manufacturing spray drying service with the installation of GEA Niro Mobile Minor equipment in a new dedicated area in its 4,000 sq. ft EU GMP plant.
The new equipment, which involves a significant investment for the company, will be installed and qualified in mid-2018 and will give Idifarma spray drying capacity for niche commercial products and clinical batches.
Luis Oquiñena, general manager and co-founder of Idifarma said: “We are excited to announce this new service and very proud to be at the forefront of spray drying technology. By making this investment, we will be able to provide contract manufacturing services for intermediate products, and for oral solid drugs we can continue until the finished dosage forms.
“This investment is driven by significant client demand, with the market looking for spray drying solutions as a suitable technology to improve the bioavailability of poorly soluble drugs. Idifarma now has all the ingredients to support our customers’ spray drying projects at different scales and contribute to accelerated drug development and manufacturing timelines.”
This announcement follows recent investment in both serialisation and capsule filling capabilities and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small commercial and clinical batches.
Oquiñena added: “Our investment in new technologies reflects our continued success within the CDMO market and our intent to further grow our business with specialised capabilities. As well as new technologies we are also investing in qualified and experienced staff to deliver our services and now have 120 employees on site. As customer demand for our niche CDMO services continues to grow we fully expect both investments and staff numbers to increase steadily in the coming year.”
FDA orders ranitidine withdrawal due to nitrosamine contamination risk
2 Apr 2020
US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...Read more
UPDATED: COVID-19 PHARMA TRACKER
2 Apr 2020
The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…Read more
China focused on meeting international API demand amid pandemic, say officials
1 Apr 2020
China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials Tuesday.Read more
New blood test able to detect 50 cancer types
31 Mar 2020
Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.Read more
Cambrex names Troy Player as head of early stage development and testing
31 Mar 2020
Cambrex has appointed pharma industry veteran, Troy Player, as president, early stage development and testing, the contract development and manufacturing organisation said Tuesday.Read more
CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility
31 Mar 2020
The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered with ChargePoint Technology to ensure the sterility of its drug substance mixing process.Read more
EMA to only issue electronic medicines certificates during COVID-19 pandemic
30 Mar 2020
The European Medicines Agency (EMA) said Monday it will only issue electronically signed and authenticated certificates for human and veterinary medicines in place of printed ones so it can continue to provide the documents during the COVID-19 pandemic...Read more
PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?
30 Mar 2020
Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.Read more
New device offers a convenient way to monitor compressed air for viable particles
30 Mar 2020
Specialist cleanroom microbiology solutions company offers the new SAS Super Pinocchio CR compressed air sampling device.Read more
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown
25 Mar 2020
Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation